Exicure (XCUR) announced it has completed patient enrollment in its ongoing Phase 2 clinical trial evaluating the safety and efficacy of GPC-100 in combination with propranolol and G-CSF in multiple myeloma patients undergoing autologous stem cell transplant.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on XCUR: